Factor VIII safety: plasma-derived versus recombinant products
- PMID: 21627925
- PMCID: PMC3200403
- DOI: 10.2450/2011.0092-10
Factor VIII safety: plasma-derived versus recombinant products
References
-
- Pool JG, Gershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature. 1964;203:312. - PubMed
-
- Pool JG, Shannon AE. Production of high-potency concentrates of antihaemophilic globulin in a closed-bag system. N Engl J Med. 1965;273:1443–7. - PubMed
-
- Brinkhous KM, Shanbrom E, Roberts HR, et al. A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors. JAMA. 1968;205:613–7. - PubMed
-
- Centers for Disease Control and Prevention (CDC) Pneumocystis carinii pneumonia among persons with hemophilia A. MMWR Morb Mortal Wkly Rep. 1982;31:365–7. - PubMed
-
- Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305:1425–31. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical